MSOS AdvisorShares Pure US Cannabis ETF Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:15
Apr 30
Apr 30
US cannabis can rise 400%
U.S. cannabis companies are massively undervalued due to regulatory overhang, but the DEA has begun accepting applications for licenses under full descheduling, which will eliminate the 280E tax burden, enable interstate commerce, and unlock economies of scale. This could lead to a 400% move in the sector over a couple of years. The MSOS ETF is a direct way to play this.
HIGH
20:10
Apr 23
Apr 23
Cannabis sector is a buying opportunity.
The U.S. cannabis sector is a massive buying opportunity because rescheduling to Schedule 3 widens the investor pool, brings back institutional money, reduces cost of capital, and will lead to significant consolidation and a valuation reset.
HIGH
19:38
Apr 22
Apr 22
Marijuana reclassification lowers taxes, spurs M&A.
The reclassification of marijuana to Schedule III will lower effective tax rates for U.S. cannabis companies from 41% to about 10%, spurring merger and acquisition activity in the sector, although it does not provide banking access or federal legalization.
HIGH
19:09
Apr 22
Apr 22
Tax relief will spur marijuana sector M&A.
The reclassification of marijuana is expected to provide significant tax relief (from 40% down to 8-10%) for cannabis companies under section 280E, which will spur merger and acquisition activity in the sector.
MED
17:10
Apr 22
Apr 22
Cannabis rescheduling to Schedule III is expected, allowing business expense deductions and medical recognition. This improves profitability and legal standing for U.S. cannabis companies, driving ETF appreciation. MSOS rallied 25% on news and may continue upward as rescheduling finalizes. Rescheduling delay or failure; structural industry headwinds remain.
MED
16:51
Apr 20
Apr 20
Cannabis rescheduling will benefit established premium operators.
The potential federal rescheduling of cannabis to Schedule III is a major positive catalyst that will improve access and research, benefiting established operators producing high-quality indoor flower as state-level legalization continues to expand.
MED
11:01
Mar 24
Mar 24
US cannabis was noted as the top-performing sector in the previous session. Sector rotation and momentum might finally be favoring beaten-down cannabis stocks. Go long on US cannabis as a momentum play outside of the geopolitical chop. Cannabis has a history of false breakouts and regulatory delays.
LOW
20:43
Dec 15
Dec 15
1. THE FACT: Trump is considering reclassifying marijuana.
2. THE BRIDGE: Reclassifying marijuana, potentially to a less restrictive schedule, could significantly ease regulatory burdens, open up banking services, and expand market access for cannabis companies. This would be a major positive catalyst for the entire cannabis sector.
3. THE VERDICT: Potential marijuana reclassification is a strong positive catalyst for cannabis stocks.
About MSOS Analyst Coverage
Buzzberg tracks MSOS (AdvisorShares Pure US Cannabis ETF) across 5 sources. 6 bullish vs 0 bearish calls from 7 analysts. Sentiment: predominantly bullish (75%). 8 total trade ideas tracked.